Glenmark Pharma launches Adalimumab in India

Glenmark Pharmaceuticals has launched the biosimilar drug Adalimumab in India. The drug will be marketed under a licensing agreement with Cadila Healthcare Ltd. It is used in the treatment of Plaque Psoriasis and Rheumatoid Arthritis is the spin off version of US drug maker AbbVie which sells the drug in the name of Humira. Adalimumab biosimilar in India was first launched by Zydus in 2014.

Company Profile : Glenmark Pharma Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.